The Relative Strength (RS) Rating for Centessa Pharma ADR climbed into a new percentile Friday, with a rise from 75 to 85.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
History reveals that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves.
Centessa Pharma ADR is not currently offering a proper buying opportunity. See if the stock goes on to form a sound pattern that could kick off a new climb.
The company showed 0% EPS growth last quarter, while sales growth came in at -100%. Look for the next report on or around May 19.
Centessa Pharma ADR holds the No. 15 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Tempus AI are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
